Kyushu University Academic Staff Educational and Research Activities Database
List of Papers
Isamu Okamoto Last modified date:2019.06.25

Lecturer / Research Institute for Disease of the Chest, Graduate School of Medical Sciences, Kyushu University / Respiratory Medicine / Kyushu University Hospital


Papers
1. Takamori S., Takada K., Azuma K., Jogo Y., Kinoshita F., Kozuma Y., Matsubara T., Haratake N., Akamine T., Toyokawa G., Hirai F., Tagawa T., Okamoto I., Nakanishi Y., Kawahara A., Akiba J., Oda Y. & Maehara Y., Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer., Anticancer Research, 38(10), 5903-5907, 2018.04.
2. Takamori S., Takada .K, Toyokawa G., Azuma K., Shimokawa M., Jogo T., Yamada Y., Hirai F., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y. , PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer., Anticancer Rsearch , 38(10), 5897-5901
, 2018.04.
3. Kiura K., Imamura F., Kagamu H., Matsumoto S., Hida T., Nakagawa K., Satouchi M., Okamoto I., Takenoyama M., Fujisaka Y., Kurata T., Ito M., Tokushige K., Hatano B. & Nishio M. , Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset., Japanese Journal of Clinical Oncology , 48(4), 367-375, 2018.04.
4. Akamine T., Takada K., Toyokawa G., Kinoshita F., Matsubara T., Kozuma Y., Haratake N., Takamori S., Hirai F., Tagawa T., Okamoto T., Yoneshima Y., Okamoto I., Shimokawa M., Oda Y., Nakanishi Y. & Maehara Y. , Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers., Journal of Surgical Oncology, 27(1), 88-94, 2018.03.
5. Kato T., Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Tai L., Yu W., Khaznadar T., Tajima K., Shibata M., Seki A. & Yamamoto N. , Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): extended safety follow-up

, Drug Safety , 41(2), 229-237
, 2018.02.
6. Takamori S., Takada K., Azuma K., Jogo T., Shimokawa M., Toyokawa G., Hirai F., Tagawa T., Kawahara A., Akiba J., Okamoto I., Nakanishi Y., Oda Y., Hoshino T. & Maehara Y., Prognostic impact of programmed death-ligand 2 expression in primary lung adenocarcinoma patients, Annals of Surgical Oncology, 38(10), 5903-5907, 2018.04.
7. Kiura K., Yoh K., Katakami N., Nogami N., Kasahara K., Takahashi T., Okamoto I., Cantarini M., Hodge R. & Uchida H. , Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples., Cancer Science, 109(4), 1177-1184, 2018.04.
8. Ryu S., Hayashi M., Aikawa H., Okamoto I., Fujiwara Y & Hamada A. , Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study., British Journal of Pharmacology , 175(1), 29-37, 2018.04.
9. Yabuuchi H., Kawanami S., Iwama E., Okamoto I., Kamitani T., Sagiyama K., Yamasaki Y. & Honda H. , Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups., Radiology , 286(2), 685-695
, 2018.02.
10. Reungwetwattana T., Nakagawa K., Cho BC., Cobo M., Cho EK., Bertolini A., Bohnet S., Zhou C., Lee KH., Nogami N., Okamoto I., Leighl N., Hodge R., McKeown A., Brown AP., Rukazenkov Y., Ramalingam SS. & Vansteenkiste J. , CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer., Journal of Clinical Oncology, 36, 33, 3290-3297, 2018.11.
11. 184. Soria JC., Ohe Y., Vansteenkiste J., Reungwetwattana T., Chewaskulyong B., Lee KH., Dechaphunkul A., Imamura F., Nogami N., Kurata T., Okamoto I., Zhou C., Cho BC., Cheng Y., Cho EK., Voon PJ., Planchard D., Su WC., Gray JE., Lee SM., Hodge R., Marotti M., Rukazenkov Y., Ramalingam SS.; FLAURA , Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer., New England Journal of Medicine , 378, 2, 113-125, 2018.01.
12. Takamori S., Toyokawa G., Okamoto I., Takada K, Kinoshita F., Kozuma Y., Matsubara T., Haratake N., Akamine T., Mukae N., Hirai F., Tagawa T., Oda Y., Iwaki T., Iihara K., Nakanishi Y. & Maehara Y. , Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer., Anticancer Research , 38, 1, 553-557, 2018.04.
13. Akamatsu H., Katakami N., Okamoto I., Kato T., Kim YH., Imamura F., Shinkai M., Hodge RA., Uchida H. & Hida T. , Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial., Cancer Science, 109, 6, 1930-1938 , 2018.06.
14. Kimura S., Tanaka K., Harada T., Liu R., Shibahara D., Kawano Y., Nakanishi Y. & Okamoto I. , Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay., Cancer Science , 109, 11, 3657-3661, 2018.11.
15. Kimura S., Harada T., Ijichi K., Tanaka K., Liu R., Shibahara D., Kawano Y., Otsubo K., Yoneshima Y., Iwama E., Nakanishi Y. & Okamoto I. , Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer., Lung Cancer , 120, 98-107, 2018.06.
16. Tanaka K., Yanagihara T., Ikematsu Y., Inoue H., Ota K., Kashiwagi E., Suzuki K., Hamada N., Takeuchi A., Tatsugami K., Eto M., Ijichi K., Oda Y., Otsubo K., Yoneshima Y., Iwama E., Nakanishi Y. & Okamoto I. , Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade., Oncotarget , 9, 55, 30587-30593 , 2018.07.
17. Otsubo K., Kishimoto J., Kenmotsu H., Minegishi Y., Ichihara E., Shiraki A., Kato T., Atagi S., Horinouchi H., Ando M., Kondoh Y., Kusumoto M., Ichikado K., Yamamoto N., Nakanishi Y. & Okamoto I. , Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non–small cell lung cancer with idiopathic pulmonary fibrosis, Clinical Lung Cancer, 19, 1, e5-e9, 2018.01.
18. Iwama E., Sakai K., Azuma K., Harada D., Nosaki K., Hotta K., Nishio M., Kurata T., Fukuhara T., Akamatsu H., Goto K., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I. , Exploration of resistance mechanisms for EGFR-TKIs based on plasma analysis by digital PCR and next-generation sequencing., Cancer Science , 109 , 3921-3933, 2018.04.
19. Anai S., Iwama E., Yoneshima Y., Otsubo K., Tanaka K., Nakanishi Y. & Okamoto I. , Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients, Lung Cancer, 126, 156-161, 2018.12.
20. Kawano Y., Sasaki T., Yamaguchi H., Hirano K., Horiike A., Satouchi M., Hosokawa S., Morinaga R., Komiya k., Inoue K., Fujita Y., Toyozawa R., Kimura T., Takahashi K.,Nishikawa K.,Kishimoto J., Nakanishi Y. &  Okamoto I. , Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non–small cell lung cancer, Lung Cancer, 125, 136-141, 2018.11.
21. Yoneshima Y., Ijichi K., Anai S., Ota K., Otsubo K., Iwama E., Tanaka K., Oda Y., Nakanishi Y. & Okamoto I. , PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements., Lung Cancer, 118, 36-40, 2018.04.
22. Tanaka K., Isse K., Fujihira T., Takenoyama M,. Saunders L., Bheddah S., Nakanishi Y. & Okamoto I., Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.

, Lung Cancer, 115, 116-120, 2018.01.
23. Shibahara D., Tanaka K., Iwama E., Kubo N., Ota K., Azuma K., Harada T., Fujita J. Nakanishi Y. & Okamoto I., Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.

, Journal of Thoracic Oncology , 13, 7, 926-937, 2018.07.
24. Okamoto I., Morita S., Tashiro N., Imamura F., Inoue A., Seto T., Yamamoto N., Ohe Y., Nakagawa K. & Fukuoka M. , Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

, Lung Cancer, 117, 14-19, 2018.03.
25. Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay , Ota K., Harada T.*, Otsubo K., Fujii A., Tsuchiya Y., Tanaka K., Okamoto I. & Nakanishi Y., Oncotarget, 8, 42, 72127-72132, 2017.09.
26. Yoneshima Y., Morita S., Ando M., Miura S., Yoshioka H., Abe T., Kato T., Kondo M., Hosomi Y., Hotta K., Yamamoto N., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I.* , Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer, Clinical Lung Cancer , 18, 1, 100-103, 2017.01.
27. Kawano Y., Iwama E., Tsuchihashi K., Shibahara D., Harada T., Tanaka K., Nagano O., Saya H., Nakanishi Y. & Okamoto I.* , CD44 variant–dependent regulation of redox balance in EGFR mutation–positive non–small cell lung cancer: A target for treatment
, Lung Cancer, 72-78, 2017.11.
28. Tanaka K., Nosaki K., Otsubo K., Azuma K., Sakata S., Ouchi H., Morinaga R., Wataya H., Fujii A., Nakagaki N., Tsuruta N., Takeshita N., Iwama E., Harada T., Nakanishi Y. & Okamoto I.* , Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutation.
, Oncotarget, 8, 40, 68123-68130, 2017.09.
29. Hayashi H.*, Chiba Y., Sakai K., Fujita T., Yoshioka H., Sakai D., Kitagawa C., Naito T., Takeda K., Okamoto I., Mitsudomi T., Kawakami Y., Nishio K., Nakamura S., Yamamoto N. & Nakagawa K., A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study
, Clinical Lung Cancer, 2017.05.
30. Kato T.*, Seto T., Nishio M., Goto K., Yamamoto N., Okamoto I., Tai L., Yu W., Khaznadar T., Tajima K., Shibata M., Seki A. & Yamamoto N. , Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): extended safety follow-up, Drug Safety, 2017.10.
31. Ryu S., Hayashi M., Aikawa H., Okamoto I., Fujiwara Y & Hamada A.* , Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study., British Journal of Pharmacology , 2017.10.
32. Yabuuchi H.*, Kawanami S., Iwama E., Okamoto I., Kamitani T., Sagiyama K., Yamasaki Y. & Honda H., Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.
, Radiology, 2017.10.
33. Takegawa N, Yonesaka K, Sakai K, Ueda H, Watanabe S, Nonagase Y, Okuno T, Takeda M, Maenishi O, Tsurutani J, Satoh T, Okamoto I, Nishio K, Tamura T, Nakagawa K. , HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer.

, Oncotarget 2016; 7(3), 3453-3460, 2016.03.
34. Yonesaka K, Hirotani K, Kawakami H, Takeda M, Kaneda H, Sakai K, Okamoto I, Nishio K, Jänne P, Nakagawa K, Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib
, Oncogene 2016; 35(7): , 878-886, 2016.07.
35. Takeda M, Yamanaka T, Seto T, Hayashi H, Azuma K, Okada M, Sugawara S, Daga H, Hirashima T, Yonesaka K, Urata Y, Murakami H, Saito H, Kubo A, Sawa T, Miyahara E, Nogami N, Nakagawa K, Nakanishi Y, Okamoto I, Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (WJOG 5910L): an open-label, randomized, phase II trial


, Cancer 2016; 122 (7), 1050-1059, 2016.07.
36. Kawakami H, Okamoto I, MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.

, Gastric Cancer 2016, 687-695, 2016.03.
37. Inoue A, Yoshida K, Morita S, Imamura F, Seto T, Okamoto I, Nakagawa K, Yamamoto N, Muto S, Fukuoka M , Characteristics and overall survival of EGFR mutation-positive non-small cell lung
cancer treated with EGFR tyrosine kinase inhibitors: A Retrospective Analysis for
1,660 Japanese patients
, Japanese Journal of Clinical Oncology 2016, 462-467, 2016.05.
38. Sakata S, Saeki S, Okamoto I (Correspondence author), Otsubo K, Komiya K, Morinaga R, Yoneshima Y, Koga Y, Enokizu A, Kishi H, Hirosako S, Yamaguchi E, Aragane N, Fujii S, Harada T, Iwama E, Semba H, Nakanishi Y, Kohrogi H , Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301

, Lung Cancer 2016, 41-45, 2016.09.
39. Iwama E, Okamoto I, Yabuuchi H, Takayama K, Harada T, Matsuo Y, Tokunaga S, Baba E, Nakanishi Y , Characteristics of Smoking Patients with Lung Cancer with Emphysematous Bullae , Journal of Thoracic Oncology 2016 , 1586-1590, 2016.09.
40. Yang J, Sequist L, Zhou C, Schuler M, Geater S, Mok T, Hu C, Yamamoto N, Feng J, O’Byrne K, Lu1 S, Hirsh V, Huang Y, Sebastian1 M, Okamoto I, Dickgreber N, Shah R, Märten1 A, Massey D, Wind S, Wu Y, Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-
positive lung adenocarcinoma: post-hoc analyses of the randomized LUX-Lung 3
and 6 trials

, Annals of Oncology 2016; 27(11), 2103-2110, 2016.11.
41. Nosaki K, Satouchi M, Kurata T, Yoshida T , Okamoto I, Katakami N, Imamura F, Tanaka K, Yamane Y, Yamamoto N, Kato T, Kiura K, Saka H, Yoshioka H, Watanabe K, Mizuno K, Seto T, Re-biopsy status among non-small cell lung cancer patients in Japan: a
retrospective study

, Lung Cancer 2016; Nov;101, 1-8, 2016.11.
42. Azuma K, Hirashima T, Yamamoto N, Okamoto I, Takahashi T, Nishio M, Hirata T, Kubota K, Kasahara K, Hida T, Yoshioka H, Nakanishi K, Akinaga S, Nishio K, Mitsudomi T, Nakagawa K. , Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib


, ESMO open 2016; 1(4): e000063, 2016.11.
43. Hibi M, Kaneda H, Tanizaki J, Sakai K, Togashi Y, Terashima M, De Velasco MA, Fujita Y, Banno E, Nakamura Y, Takeda M, Ito A, Mitsudomi T, Nakagawa K, Okamoto I, Nishio K., FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib

, Cancer Science, 1667-1676, 2016.11.
44. Ebi N, Tokunaga S, Itoh K, Okamoto I, Edakuni N, Fujii S, Watanabe K, Hayashi S, Maeyama T, Nakanishi Y., Multicenter cooperative observation study of idiopathic pulmonary fibrosis with non-small cell lung cancer

, World Journal of Respirology 2016; 6(1), 42-48, 2016.12.
45. Ogata H., Okamoto I., Yoshimoto G., Obara T., Ijichi K., Iwama E., Harada T., Akashi K. & Nakanishi Y. , Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
, Respiratory Investigation , 181-183, 2017.03.
46. Ikematsu Y., Yoneshima Y., Ijichi K., Tanaka K., Harada T., Oda Y, Nakanishi Y. & Okamoto I.* , Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1
, Lung Cancer , 2017.07.
47. Yanagihara T., Tanaka K., Ota K., Kashiwagi E., Takeuchi A., Tatsugami K, Eto M, Nakanishi Y. & Okamoto I.* , Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment

, Annals of Oncology 28(8), 2038-2039, 2017.08.
48. Fukuda M.,* Shimada M., Kitazaki T., Nagashima S., Hashiguchi K., Ebi N., Takayama K., Nakanishi Y., Semba H., Harada T., Seto T., Okamoto I., Ichinose Y. & Sugio K., A phase I study of irinotecan for previously treated lung cancer patients with the  
UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu

, Thoracic Cancer , 40-45, 2017.01.
49. 17. Takamori S, Toyokawa G*, Okamoto I, Takada K, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Mukae N, Shoji F, Okamoto T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y. , Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-Small-Cell Lung Cancer.
ANTICANCER RESEARCH 37(8), 4223-4228 (2017)
, ANTICANCER RESEARCH 37(8), 4223--4228 (2017), 2017.08.
50. Hidaka N., Iwama E*., Kubo N., Harada T., Miyawaki K., Tanaka K., Okamoto I., Baba E., Akashi K., Sasaki H. & Nakanishi Y., Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer

, Lung Cancer, 75-82, 2017.06.
51. Iwama E., Sakai K., Azuma K., Harada T., Harada D., Nosaki K., Hotta K., Ohyanagi F., Kurata T., Fukuhara T., Akamatsu H., Goto K., Shimose T., Kishimoto J., Nakanishi Y., Nishio K. & Okamoto I.*, Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations, Annals of Oncology, 136-141, 2017.01.
52. Iwama E., Goto Y., Murakami H., Harada T., Tsumura S., Sakashita H., Mori Y., Nakagaki N., Fujita Y., Seike M., Bessho A., Ono M., Okazaki A., Akamatsu H., Morinaga R., Ushijima S., Shimose T., Tokunaga S., Hamada H., Yamamoto N., Nakanishi Y., Sugio K. & Okamoto I.* , Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer
and a poor performance status (Lung Oncology Group in Kyushu 1401)
, Journal of Thoracic Oncology , 1161--1166 , 2017.12.
53. Okamoto I., Schuette H., Stinchcombe T., Rodorigues-Pereira J., Antonio B., Chen J., Liu J., John W.* & Zinner R. , Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies
, Current Medical Research and Opinion , 937-941, 2017.05.
54. Otsubo K., Kishimoto J., Kenmotsu H., Minegishi Y., Ichihara E., Shiraki A., Kato T., Atagi S., Horinouchi H., Ando M., Kondoh Y., Kusumoto M., Ichikado K., Yamamoto N., Nakanishi Y. & Okamoto I.* , Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non–small cell lung cancer with idiopathic pulmonary fibrosis
, Clinical Lung Cancer, 2017.06.
55. Otsubo K., Nosaki K., Imamura C., Ogata H., Fujita A., Sakata S., Hirai F., Toyokawa G., Iwama E., Harada T., Seto T., Takenoyama T., Ozaki M., Mushiroda T., Inada M., Kishimoto J., Tsuchihashi K., Suina K., Nagano O., Saya H., Nakanishi Y. & Okamoto I.* , Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non–small cell lung cancer



, Cancer Science 2017; 108(9): , 108, 9, 1843-1849, 2017.09.
56. Langer CJ., Hirsh V., Okamoto I., Lin FJ., Wan Y., Whiting S., Ong TJ., Renschler MF., Botteman MF., Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.

, British Journal of Cancer 2015; 113(1): 20-29, 113, 1, 20-29, 2015.06.
57. Fijii A., Harada T., Iwama E., Ota K., Furuyama K., Ijichi K., Okamoto T., Okamoto I., Takayama K., Nakanishi Y., Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.

, Cancer Genetics , 208, 5, 271-278, 2015.05.
58. Yonesaka K., Hirotani K., Kawakami H., Takeda M., Kaneda H., Sakai K., Okamoto I., Nishio K., Jänne P., Nakagawa K., Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

, Oncogene, 10, 11, 2015.05.
59. Abe H., Kawahara A., Azuma K., Taira T., Takase Y., Fukumitsu T., Murata K., Yamaguchi T., Akiba J., Ishii H., Okamoto I., Hoshino T., Takamori S., Kage M., Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinoma: A comparative study between small biopsy and excision samples
, Journal of Thoracic Oncology , 10, 5, 800-805, 2015.05.
60. Yoneshima Y., Okamoto I., Arima-Omori M., Kimura S., Hidaka-Fujimoto N., Iwama E., Harada T., Takayama K., Nakanishi Y., Infected complex renal cysts during crizotinib therapy in a patient with non–small cell lung cancer positive for ALK rearrangement

, Investigational New Drugs , 33, 2, 510-512, 2015.04.
61. Takeda M., Okamoto I., Nakagawa K., Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
, Lung Cancer, 88, 1, 74-79, 2015.04.
62. Li H., Wang S., Takayama K., Harada T,, Okamoto I., Iwama E., Fujii A., Ota K., Hidaka N., Kawano Y., Nakanishi Y., Nicotine induces resistance to erlotinib via cross-talk between α 1 nAChR and EGFR in the non-small cell lung cancer xenograft model.
Lung Cance
, Lung Cancer, 88, 1, 1-8, 2015.04.
63. Fujisaka Y., Kurata T., Tanaka K., Kudo T., Okamoto K., Tsurutani J., Kaneda H., Okamoto I., Namiki M., Kitamura C., Nakagawa K., Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors.
, Investigational New Drugs , 33, 2, 380-388, 2015.04.
64. Yonesaka K., Satoh T., Ueda S., Yoshida T., Takeda M., Shimizu T., Okamoto I., Nishio K., Tamura T., Nakagawa K., Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer

, ANTICANCER RESEARCH, 35, 3, 1683-1689, 2015.03.
65. Okamoto I., Miyazaki M., Takeda M., Terashima M., Azuma K., Hayashi H., Kaneda H., Kurata T., Tsurutani J., Seto T., Hirai F., Konishi K., Sarashina A., Yagi N., Kaiser R., Nakagawa K., The tolerability of nintedanib (BIBF 1120) in combination with docetaxel: a Phase 1 study in Japanese patients with previously treated non-small-cell lung cancer.

, Journal of Thoracic Oncology, 10, 2, 346-352, 2015.02.
66. Hayashi H., Arao T., Togashi Y., Kato H., Fujita Y., De Velasco MA., Kimura H., Matsumoto K., Tanaka K., Okamoto I., Ito A., Yamada Y., Nakagawa K., Nishio K., The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer
, Oncogene, 34, 2, 199-208, 2015.01.
67. Sakai K., Takeda M., Okamoto I., Nakagawa K., Nishio K., Multiple regulatory mechanism of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF promoter.
, Oncology Letters, 9, 1, 405-410, 2015.01.
68. Naito T., Seto T., Takeda K., Goto K., Okamoto I., Nakagawa K., Ohba T., Murakami H., Takahashi T., Yamanaka T., Yamamoto N., Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non–small-cell lung cancer., Lung Cancer, 86, 3, 339-343, 2014.12.
69. Kawakami H., Okamoto I., Yonesaka K., Okamoto K., Shibata K., Shinkai Y., Sakamoto H., Kitano M., Tamura T., Nishio K., Nakagawa K., The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells, Oncotarget, 5, 23, 11847-11856, 2014.12.
70. Li H, Takayama K, Wang S., Shiraishi Y., Gotanda K., Harada T., Furuyama K., Iwama E., Okamoto I, Nakanishi Y, Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression., Cancer Chemother Pharmacol. , 74, 6, 1297-1305, 2014.12.
71. Seto T., Kato T., Nishio M., Goto K., Atagi S., Hosomi Y., Yamamoto N., Hida T., Maemondo M., Nakagawa K., Nagase S., Okamoto I., Yamanaka T., Tajima K., Harada R., Fukuoka M., Yamamoto N., Erlotinib alone or with bevacizumab as a first-line therapy in patients with advanced non-squamous non–small-cell lung cancer harbouring epidermal growth factor receptor mutations (JO25567): a randomised phase II study
, Lancet Oncology, 15, 11, 1236-1244, 2014.10.
72. Azuma K., Ota K., Kawahara A., Hattori S., Iwama E., Harada T., Matsumoto K., Takayama K., Takamori S., Kage M., Hoshimo T., Nakanishi Y., Okamoto I., Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer.
, Annal s of Oncology, 25, 10, 1935-1940, 2014.10.
73. Yoshida T., Zhang G., Smith MA., Lopez AS., Bai Y., Li J., Fang B., Koomen J., Rawal B., Fisher KJ., Chen AY., Kitano M., Morita Y., Yamaguchi H., Shibata K., Okabe T., Okamoto I., Nakagawa K., Haura EB., Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer.
, Clin Cancer Res., 20, 15, 4059-4074, 2014.08.
74. Okamoto K., Okamoto I., Takeda M., Kobayashi S., Takeda K., Nakamatsu K., Nishimura Y., Nakagawa K., A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancer.
, Japanese Journal of Clinical Oncology, 44, 8, 743-748, 2014.08.
75. Murakami H., Yamanaka T., Seto T., Suigio K., Okamoto I., Sawa T., Hirashima T., Takeda K., Atagi S., Fukuoka M., Nakanishi Y., Nakagawa K., Yamamoto N., A Phase II Study of Zoledronic Acid Combined with Docetaxel for Non–small-cell Lung Cancer: West Japan Oncology Group
, Cancer Science, 105, 8, 989-995, 2014.08.
76. Park KS., Raffeld M., Moon YW., Xi L, Bianco C., Pham T., Lee LC., Mitsudomi T., Yatabe Y., Okamoto I., Subramaniam D., Mok T., Rosell R., Luo J., Salomon DS., Wang Y., Giaccone G., CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance..
, Journal of Clinical Investigation, 124, 7, 3003-3015, 2014.07.
77. Okamoto I., Sakai K., Morita S., Yoshioka H., Kaneda H., Takeda K., Hirashima T., Kogure Y., Kimura T., Takahashi T., Atagi S., Seto T., Sawa T., Yamamoto M., Satouchi M., Okuno M., Nagase S., Takayama K., Tomii K., Maeda T., Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study
, Oncotarget, 5, 8, 2293-2230, 2014.04.
78. Takeda K., Okamoto I., Nakagawa K., Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small cell lung cancer treated with gefitinib or erlotinib

, Journal of Thoracic Oncology, 9, 2, 200-204, 2014.02.
79. Hirsh V., Okamoto I., Hon JK., Page RD., Orshi J., Sakai H., Zhang H., Renschler MF., Socinski MA., Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer.

, Journal of Thoracic Oncology, 9, 1, 83-90, 2014.01.
80. Tsuya A., Kurata T., Tamiya A., Okamoto I., Ueda S., Sakai D., Sugimoto N., Matsumoto K., Goto I., Yamamoto N., Fukuoka M., Nakagawa K., A phase II study of cisplatin /S-1 in patients with carcinomas of unknown primary site.
, Investigational New Drugs , 31, 6, 1568-1572, 2013.12.
81. Hironaka S., Ueda S., Yasui H., Nishina T., Tsuda M., Tsumura T., Sugimoto N., Shimodaira H., Tokunaga S., Moriwaki T., Esaki T., Nagase M., Fujitani K., Yamaguchi K., Ura T., Hamamoto Y., Morita S., Okamoto I., Boku N., Hyodo I., A Randomized, Open-label, Phase III Study Comparing Irinotecan with Paclitaxel for Treatment of Advanced Gastric Cancer Refractory to Combination Chemotherapy using Fluoropyrimidine plus Platinum: WJOG4007 Trial
, Journal of Clinical Oncology , 31, 35, 4438-4444, 2013.12.
82. Kawakami H., Okamoto I., Terao K., Sakai K., Suzuki M., Ueda S., Tanaka K., Kuwata K., Morita Y., Ono K., Nishio K., Nishimura Y., Doi K., Nakagawa K., Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma
, Cancer Medicine, 2, 6, 933-941, 2013.12.
83. Hayashi H., Okamoto I., Ueda S., Tanaka K., Okamoto K., Kawakami H., Nishina S., Takeda M., Fujisaka Y., Satoh T., Terao K., Nishimura Y., Doi K., Nakagawa K., Phase I Pharmacokinetic Study of S-1 Granules and Nedaplatin for Advanced Head and Neck Cancer
, Anticancer Reseach, 33, 12, 5699-5705, 2013.12.
84. Okamoto W., Yoshino T., Takahashi T., Okamoto I., Ueda S., Tsuya A., Boku N., Nishio K., Fukuoka M., Yamamoto N., Nakagawa K., A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors
, Cancer Chemotherapy and Pharmacology, 72, 5, 1063-1071, 2013.11.
85. Li J., Bennett K., Stukaloy A., Fang B., Zhang G., Yoshida T., Okamoto I., Kim JY., Song L., Bai Y., Qian X., Rawal B., Schell M., Grebien F., Winter G., Rix U., Eschrich S., Koomen J., Superti-Furga G., Haura EB., Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.
, 5, 9, 2013.11.
86. Okamoto I., Aoe K., Kato T., Hosomi Y., Yokoyama A., Imamura F., Hirashima T., Nishio M., Nogami N., Okamoto H., Saka H., Yamamoto N., Yoshizuka N., Sekiguchi R., Kiyosawa K., Nakagawa K., Tamura T., Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small cell lung cancer.
, Investigational New Drugs, 31, 5, 1275-1282, 2013.10.
87. Socinski MA., Okamoto I., Hon JK., Hirsh V., Dakhil SR., Page RD., Orsini J, Yamamoto N., Zhang H., Renschler MF., Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
, Annals of Oncology , 24, 9, 2390-2396, 2013.09.
88. Kawakami H., Okamoto I., Hayashi H., Taguri M., Morita S., Nakagawa K., Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

, European Journal of Cancer , 49, 14, 3003-3009, 2013.09.
89. Kawakami H., Okamoto I., Okamoto W., Takeda M., Ueda S., Kudo T., Nishina S., Fujisaka Y., Miyazaki M., Tsurutani J., Kurata T., Nakagawa K., Practical use of gemcitabine and cisplatin combination therapy as first-line treatment for Japanese patients with advanced biliary tract cancer
, Journal of Cancer Therapy , 4, 6, 1068-1073, 2013.08.
90. Satouchi M., Okamoto I., Sakai H., Yamamoto N., Ichinose Y., Ohmatsu H., Nogami N., Takeda K., Mitsudomi T., Kasahara K., Negoro S., Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
, Lung Cancer, 81, 1, 97-101, 2013.07.
91. Hasegawa Y., Okamoto I., Takezawa K., Miyazaki M., Tsurutani J., Yonesaka K., Morinaga R., Tsuya A., Terashima M., Kudoh T., Azuma K., Kurata T., Nishikawa T., Fukuoka M., Nishimura T., Nakagawa K., A phase I study of S-1with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer.

, Investigational New Drugs., 31, 3, 599-604, 2013.06.
92. Kogure Y., Ando M., Saka H., Chiba Y., Yamamoto N., Asami K., Hirashima T., Seto T., Nagase S., Otsuka K., Yanagihara K., Takeda K., Okamoto I., Aoki T., Takayama K., Yamasaki M., Kudoh S., Katakami N., Miyazaki M., Nakagawa K., Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer: Results of West Japan Oncology Group (WJOG) Study 3906L.
, Journal of Thoracic Oncology, 8, 6, 753-758, 2013.06.
93. Urata Y., Okamoto I., Takeda M., Hattori Y., Okuno K., Shimada T., Kurata T., Kaneda H., Miyazaki M., Terashima M., Tanaka K., Morita S., Nakagawa K., Negoro S., Satouchi M., Phase II study of S-1 and carboplatin plus bevacizumab followed by maintenance S-1 and bevacizumab for chemotherapy-naïve patients with advanced nonsquamous non–small cell lung cancer.
, Cancer, 119, 12, 2275-2281, 2013.06.
94. Hayashi H., Okamoto I., Taguri M., Morita S., Nakagawa K., Postprogression survival in patients with advanced non-small cell lung cancer who receive second- or third-line chemotherapy

, Clinical Lung Cancer, 2013.05.
95. Yoshioka H., Okamoto I., Morita S., Ando M, Takeda K., Seto T., Yamamoto N., Saka H., Atagi S., Hirashima T., Kudoh S., Satouchi M., Ikeda N., Iwamoto Y., Sawa T., Nakanishi Y., Nakagawa K., Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer: updated results of the West Japan Oncology Group LETS study
, Annals of Oncology, 24, 5, 1326-1331, 2013.05.
96. Ogi S., Fujita H., Kashihara M., Yamamoto C., Sonoda K., Okamoto I., Nakagawa K., Ohdo S., Tanaka Y., Kuwano M., Ono M., Sorting nexin2-mediated membarne trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.
, Cancer Science, 104, 5, 573-583, 2013.05.
97. Takeda K., Okamoto I., Nakagawa K., Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.
, Journal of Thoracic Oncology , 8, 5, 654-657, 2013.05.
98. Hayashi H., Tsurutani J., Satoh T., Masuda N., Okamoto W., Morinaga R., Terashima M., Miyazaki M., Okamoto I., Nishida Y., Tominaga S., Tokunaga Y., Yamaguchi M., Sakamoto J., Nakayama T., Nakagawa K., Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.

, Breast Cancer , 20, 2, 131-136, 2013.04.
99. Kiyota H., Okamoto I., Takeda M., Daga H., Naito T., Miyazaki M., Okada H., Hayashi H., Tanaka K., Terashima M., Azuma K., Murakami H., Takeda K., Yamamoto N., Nakagawa K., Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung .

, Cancer Chemotherapy and Pharmacology, 71, 4, 859-865, 2013.04.
100. Socinski MA., LangerCJ., Okamoto I., Hon JK., Hirsh V., Dakhil SR., Page RD., Orsini J., Zhang H., Renschler MF., Safety and Efficacy of Weekly nab®-Paclitaxel in Combination with Carboplatin as First-line Therapy in Elderly Patients with Advanced Non-small Cell Lung Cancer.

, Annals of Oncology , 24, 2, 314-321, 2013.02.
101. Kawakami H., Okamoto I., Arao T., Okamoto W., Matsumoto K., Taniguchi H., Kuwata K., Yamaguchi H., Nishio K., Nakagawa K., Yamada Y., MET amplification as a potential therapeutic target in gastric cancer.
, Oncotarget , 4, 1, 9-17, 2013.01.
102. Okamoto I., Arao T., Miyazaki M., Satoh T., Okamoto K., Tsunoda T., Nishio K., Nakagawa K., Clinical Phase I Study of Elpamotide, a Peptide Vaccine for VEGFR 2, in Patients with Advanced Solid Tumors.

, 103, 12, 2135-2138, 2012.12.
103. Takeda M., Okamoto I., Sakai K., Kawakami K., Nishio K., Nakagawa K., Clinical outcome for EML4-ALK–positive patients with advanced non–small cell lung cancer treated with first-line platinum-based chemotherapy

, Annals of Oncology, 23, 11, 2931-2936, 2012.11.
104. Takeda M., Okamoto I., Sakai K., Kawakami K., Nishio K., Nakagawa K., Clinical outcome for EML4-ALK–positive patients with advanced non–small cell lung cancer treated with first-line platinum-based chemotherapy

, Annals of Oncology, 23, 11, 2931-2936, 2012.11.
105. Tanizaki J., Okamoto I., Okabe T., Sakai K., Tanaka K., Hayashi H., Kaneda H., Takezawa K., Kuwata K., Yamaguchi H., Hatashita E., Nishio K., Nakagawa K., Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer., 18, 22, 6219-6226, 2012.11.
106. Hayashi H., Okamoto I., Kimura H., Sakai K., Nishimura Y., Nishio K., Nakagawa K., Clinical Outcome of Thoracic Radiotherapy for Locally Advanced NSCLC with EGFR Mutations or EML4-ALK, 32, 10, 4533-4537, 2012.10.
107. Takeda M., Okamoto I., Yamanaka T., Nakagawa K., Nakanishi Y., Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer (WJOG 5910L), BMC cancer, 12, 1, 327, 2012.08.
108. Okamoto W., Okamoto I., Arao T., Kuwata K., Hatashita E., Yamaguchi H., Sakai K., Yanagihara K., Nishio K., Nakagawa K., Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification.

, Molecular Cancer Therapeutics, 11, 1557-1564, 2012.07.
109. Okamoto I., Yamamoto N., Kubota K., Ohe Y., Nogami N., Murakami H., Yamaha H., Ono K., Nakagawa K., Safety and pharmacokinetic study of nab-paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer.

, Investigational New Drugs, 30, 1132-1137, 2012.06.
110. Socinski M., Bondarenko I., Karaseva N., Makhson A., Vynnychenko I., Okamoto I., Hon J., Hirsh V., Bhar P., Zhang H., Iglesias J., Renschler M., Weekly nab-Paclitaxel in Combination with Carboplatin vs Solvent-based Paclitaxel Plus Carboplatin as First-line Therapy in Patients With Advanced Non-small Cell Lung Cancer: Final Results of a Phase 3 Trial

, Journal of Clinical Oncology, 30, 17, 2055-2062, 2012.06.
111. Takeda M., Okamoto I., Tsurutani J., Oiso N., Kawada A., Nakagawa K., Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC

, Japanese Journal of Clinical Oncology, 42, 6, 528-533, 2012.06.
112. Hayashi H., Okamoto I., Morita S., Taguri M., Nakagawa K., Postprogression survival for first-line chemotherapy of patients with advanced non–small cell lung cancer

, Annals of Oncology, 23, 6, 1537-1541, 2012.06.
113. Sakai K., Okamoto I., Takezawa K., Hirashima T., Kaneda H., Takeda M., Matsumoto K., Kimura H., Fujita Y., Nakagawa K., Arao T., Nishio K., A novel mass spectrometry–based assay for diagnosis of EML4-ALK–positive non–small cell lung cancer

, Journal of Thoracic Oncology, 7, 913-918, 2012.05.
114. Okamoto I., Shimizu T., Miyazaki M., Tsurutani J., Ichikwa Y., Terashima M., Takeda M., Fumita S., Ohki E., Kimura N., Hashimoto J., Nakagawa K., Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors.
, Investigational New Drugs, 30, 639-646, 2012.04.
115. Okamoto I., Yoshioka H., Takeda K., Satouchi M., Yamamoto N., Seto T., Kasahara K., Miyazaki M., Kitamura R., Ohyama A., Hokoda N., Nakayama H., Yoshihara E., Nakagawa K., Phase I clinical study of the angiogenesis inhibitor TSU-68 combined with carboplatin and paclitaxel in chemotherapy-naïve patients with advanced non–small cell lung cancer
, Journal of Thoracic Oncology, 7, 427-433, 2012.02.
116. Tanizaki J., Okamoto I., Takezawa K., Sakai K., Azuma K., Kuwata K., Yamaguchi H., Hatashita E., Nishio K., Janne PA., Nakagawa K., Combined effect of ALK and MEK inhibitor in EML4-ALK-positive non-small-cell lung cancer cells
, British Journal of Cancer , 106, 763-767, 2012.02.
117. Tanaka K., Arao T., Tamura D., Aomatsu K., Furuta K., Matsumoto K., Kaneda H., Kubo K., Fujita Y., KimuraH., Yanagihara K., Yamada Y., Okamoto I., Nkagawa K., Nishio K., SRPX2 is Novel Chondroitin Sulfate Proteoglycan That is Overexpressed in Gastrointestinal Cancer

, PLoS One , 7, 2012.01.
118. Azuma K., Okamoto I., Kawahara A., Taira T., Nakanishima K., Hattori S., Kinoshita T., Takeda M., Nakagawa K., Takamori S., Kuwano M., Ono M., Kage M., Association of the expression of mutant EGFR protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.

, Journal of Thoracic Oncology , 7, 122-127, 2012.01.
119. Okamoto K., Okamoto I., Hatashita E., Kuwata K., Yamaguchi H., Kita A., Yamanaka K., Ono M., Nakagawa K., Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small Cell Lung Cancer Cells by Targeting Survivin, Molecular Cancer Therapeutics, 11, 204-213, 2012.01.